Table 2 Clinical trials with MDM2-MDMX inhibitors
Compound | Clinical study | Phase | Status | Clinical trial identifier |
|---|---|---|---|---|
RG7112 RO5045337 | Extension study to provide treatment to participants who have completed parent studies | 1 | Active, not recruiting | NCT01677780 |
Solid tumors | 1 | Completed | NCT01164033 | |
Patients with liposarcoma who are eligible for debulking surgery | 1 | Completed | NCT01143740 | |
Soft tissue sarcoma: treatment in combination with doxorubicin | 1 | Completed | NCT01605526 | |
AML, ALL, CML in blast phase, refractory CLL/SCLL | 1 | Completed | NCT00623870 | |
Advanced solid tumors including lymphoma | 1 | Completed | NCT00559533 | |
AML: treatment combination with cytarabine | 1 | Completed | NCT01635296 | |
RG7388 RO5503781 Idasanutlin | Essential thrombocythemia and polycythemia vera | 1 | Recruiting | NCT02407080 |
Solid tumors: determination of excretion balance, pharmacokinetics, metabolism and bioavailability | 1 | Active, not recruiting | NCT02828930 | |
Multiple myeloma: combinations with ixazomib citrate and dexamethasone | 1/2 | Recruiting | NCT02633059 | |
R/R AML: combination with cytarabine | 3 | Recruiting | NCT02545283 | |
In R/R FL in combination with obinutuzumab and in DLBCL combination with rituximab | 1b/2 | Recruiting | NCT02624986 | |
R/R AML patients not eligible for cytotoxic therapy: combination with venetoclax | 1/2 | Recruiting | NCT02670044 | |
Prostate cancer who haven’t had docetaxel: Idasanutlin with abiraterone or enzalutamide | 1/2 | Open | CRUKE/12/032 | |
Solid tumors: effect of posaconazole on pharmacokinetics, bioavailability of new formulations | 1 | Completed | NCT01901172 | |
AML: combination with cytarabine | 1 | Completed | NCT01773408 | |
Advanced malignancies except leukemia | 1 | Completed | NCT01462175 | |
SAR405838 MI-77301 | Advanced cancer | 1 | Active not recruiting | NCT01636479 |
Advanced cancer (solid tumors): combination with pimasertib | 1 | Completed | NCT01985191 | |
MK-8242 SCH 900242 | Advanced solid tumors: study of safety and pharmacokinetics | 1 | Completed | NCT01463696 |
AML: alone and in combination with cytarabine | 1 | Completed | NCT01451437 | |
AMG232 | R/R AML: combination with trametinib | 1b | Recruiting | NCT02016729 |
R/R multiple myeloma: combination with carfilzomib, lenalidomide, dexamethasone | 1 | Not yet recruiting | NCT03031730 | |
Advanced solid tumors or multiple myeloma | 1 | Active not recruiting | NCT01723020 | |
Metastatic cutaneous melanoma: combination with trametinib and dabrafenib or trametinib | 1b/2a | Recruiting | NCT02110355 | |
DS-3032b | Relapsed and/or refractory multiple myeloma | 1 | Recruiting | NCT02579824 |
Hematological malignancies: AML, ALL, CML and myelodysplastic syndrome | 1 | Recruiting | NCT02319369 | |
Advanced solid tumors or lymphomas | 1 | Recruiting | NCT01877382 | |
HDM201 | Liposarcoma in combination with LEE011 | 1b/2 | Recruiting | NCT02343172 |
Advanced solid and hematological tumors with wt-TP53 | 1 | Recruiting | NCT02143635 | |
Neuroblastoma: to match genomic aberrations at time of relapse to designed combined therapies | 1 | Recruiting | NCT02780128 | |
CGM097 | Advanced solid tumors with wt-TP53 | 1 | Active not recruiting | NCT01760525 |
ALRN-6924 | AML or advanced myelodysplastic syndrome with wt-TP53: alone or in combination with cytarabine | 1/1b | Recruiting | NCT02909972 |
Advanced solid tumors or lymphomas with wt-TP53 | 1/2a | Recruiting | NCT02264613 |